ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock OBSV vs. ITRM, SONN, KLTO, KZR, DARE, CVKD, RNTX, MBRX, MIRA, and RVPHShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Iterum Therapeutics (ITRM), Sonnet BioTherapeutics (SONN), Klotho Neurosciences (KLTO), Kezar Life Sciences (KZR), Dare Bioscience (DARE), Cadrenal Therapeutics (CVKD), Rein Therapeutics (RNTX), Moleculin Biotech (MBRX), MIRA Pharmaceuticals (MIRA), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Its Competitors Iterum Therapeutics Sonnet BioTherapeutics Klotho Neurosciences Kezar Life Sciences Dare Bioscience Cadrenal Therapeutics Rein Therapeutics Moleculin Biotech MIRA Pharmaceuticals Reviva Pharmaceuticals ObsEva (NASDAQ:OBSV) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Do analysts recommend OBSV or ITRM? Iterum Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,084.21%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Iterum Therapeutics is more favorable than ObsEva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Iterum Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, OBSV or ITRM? ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 3.24, indicating that its share price is 224% more volatile than the S&P 500. Is OBSV or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% Iterum Therapeutics N/A N/A -65.01% Do institutionals and insiders hold more shares of OBSV or ITRM? 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 2.4% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, OBSV or ITRM? Iterum Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEvaN/AN/A-$58.38M-$0.92N/AIterum TherapeuticsN/AN/A-$24.77M-$0.85-0.89 Does the media prefer OBSV or ITRM? In the previous week, ObsEva's average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score. Company Overall Sentiment ObsEva Neutral Iterum Therapeutics Neutral SummaryIterum Therapeutics beats ObsEva on 8 of the 10 factors compared between the two stocks. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$1.05B$6.10B$10.52BDividend YieldN/A4.84%5.51%4.70%P/E Ratio0.001.2885.6826.85Price / SalesN/A30.43585.01185.67Price / CashN/A17.6426.3031.10Price / BookN/A7.6513.256.72Net Income-$58.38M-$7.66M$3.30B$276.44M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050ITRMIterum Therapeutics1.4875 of 5 stars$0.67-2.6%$9.00+1,249.3%-30.3%$31.46MN/A-0.7810Gap UpSONNSonnet BioTherapeutics1.775 of 5 stars$4.54-7.2%$20.00+340.5%+5.6%$31.01M$20K0.0010KLTOKlotho Neurosciences0.649 of 5 stars$0.48-5.5%N/AN/A$29.35MN/A-1.06N/ANews CoverageKZRKezar Life Sciences3.5397 of 5 stars$3.91+8.9%$9.00+130.2%-50.7%$28.66M$7M-0.4060High Trading VolumeDAREDare Bioscience1.9465 of 5 stars$2.11+1.0%$10.00+373.9%-30.3%$28.44M$10K-0.9930News CoverageCVKDCadrenal Therapeutics2.4318 of 5 stars$13.74+2.3%$32.00+133.0%+12.8%$28.12MN/A-1.554RNTXRein Therapeutics3.0764 of 5 stars$1.15flat$10.00+769.6%N/A$26.81MN/A-0.439High Trading VolumeMBRXMoleculin Biotech3.0156 of 5 stars$0.53+7.8%$4.00+661.9%-79.6%$25.99MN/A0.0020Gap UpMIRAMIRA Pharmaceuticals0.5561 of 5 stars$1.36+2.3%N/A+17.4%$25.94MN/A-2.782RVPHReviva Pharmaceuticals3.6238 of 5 stars$0.37+20.0%$4.86+1,212.7%-46.5%$25.66MN/A-0.575News CoverageAnalyst UpgradeGap UpHigh Trading Volume Related Companies and Tools Related Companies Iterum Therapeutics Alternatives Sonnet BioTherapeutics Alternatives Klotho Neurosciences Alternatives Kezar Life Sciences Alternatives Dare Bioscience Alternatives Cadrenal Therapeutics Alternatives Rein Therapeutics Alternatives Moleculin Biotech Alternatives MIRA Pharmaceuticals Alternatives Reviva Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBSV) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
